anti-HER-2 mAb-FcgR2- FcgR4 fusion proteins (Iterative)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-HER-2 mAb-FcgR2- FcgR4 fusion proteins (Iterative)

Drug Alias Namerecombinant fusion proteins (Iterative therapeutics)anti-HER2 mAb analogs (Iterative therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesIterative Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIterative Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A